All stock lists
Maze Therapeutics, Inc. (NASDAQ:MAZE)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
31.44+0.43 (+1.37%)
Insider Score
––Not scored
MAZE Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
MAZE Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 20.00 M | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | -100.00 % | -100.00 % | — |
| Cost of Revenue | 0.00 | 444.00 K | 499.00 K | 0.00 | 649.00 K | 0.00 |
| Gross Profit | 0.00 | 19.56 M | -499.00 K | 0.00 | -649.00 K | 0.00 |
| SG&A Expense | 13.10 M | 12.40 M | 10.49 M | 7.78 M | 8.37 M | 7.82 M |
| R&D Expense | 34.94 M | 33.70 M | 27.57 M | 25.19 M | 28.11 M | 27.58 M |
| Operating Expenses | 48.03 M | 46.11 M | 37.56 M | 32.97 M | 35.83 M | 35.40 M |
| Operating Income | -48.03 M | -26.55 M | -38.06 M | -32.97 M | -36.47 M | -35.40 M |
| Pretax Income | -44.73 M | -24.21 M | -34.57 M | -30.09 M | -33.68 M | -32.79 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -44.73 M | -24.21 M | -34.57 M | -30.09 M | -33.68 M | -32.79 M |
| EPS (Basic) | -0.76 | -0.45 | -0.87 | -0.66 | -0.77 | -0.75 |
| EPS (Diluted) | -0.76 | -0.45 | -0.87 | -0.66 | -0.77 | -0.75 |
| Shares Outstanding | 59.00 M | 53.90 M | 42.98 M | 45.78 M | 43.85 M | 43.80 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.